Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 6 | 2024 | 225 | 1.820 |
Why?
|
Hyperoxaluria | 1 | 2024 | 32 | 0.900 |
Why?
|
Abducens Nerve Diseases | 1 | 2024 | 44 | 0.880 |
Why?
|
Glomerulonephritis, Membranous | 2 | 2021 | 88 | 0.870 |
Why?
|
Immunologic Factors | 3 | 2021 | 1589 | 0.790 |
Why?
|
Paranasal Sinuses | 1 | 2021 | 265 | 0.620 |
Why?
|
Renal Insufficiency | 1 | 2024 | 808 | 0.590 |
Why?
|
Nose | 1 | 2021 | 521 | 0.570 |
Why?
|
Glomerulonephritis | 1 | 2018 | 331 | 0.540 |
Why?
|
Vancomycin | 1 | 2019 | 503 | 0.500 |
Why?
|
Neutropenia | 1 | 2020 | 885 | 0.500 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3150 | 0.430 |
Why?
|
Glomerulosclerosis, Focal Segmental | 3 | 2021 | 335 | 0.430 |
Why?
|
Fever | 1 | 2020 | 1618 | 0.430 |
Why?
|
Autoimmune Diseases | 2 | 2021 | 2238 | 0.390 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 3 | 2024 | 289 | 0.380 |
Why?
|
Nephrosis, Lipoid | 2 | 2020 | 45 | 0.360 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2178 | 0.350 |
Why?
|
Sepsis | 1 | 2020 | 2585 | 0.270 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1924 | 0.270 |
Why?
|
Cyclophosphamide | 2 | 2021 | 2218 | 0.250 |
Why?
|
Curcuma | 1 | 2024 | 10 | 0.230 |
Why?
|
Oxalates | 1 | 2024 | 97 | 0.220 |
Why?
|
Immunosuppressive Agents | 4 | 2024 | 4174 | 0.210 |
Why?
|
Receptors, Phospholipase A2 | 1 | 2021 | 33 | 0.190 |
Why?
|
Vaginitis | 1 | 2021 | 49 | 0.190 |
Why?
|
Vaginal Discharge | 1 | 2021 | 25 | 0.190 |
Why?
|
Recurrence | 3 | 2024 | 8426 | 0.190 |
Why?
|
Filgrastim | 1 | 2020 | 132 | 0.180 |
Why?
|
Hematologic Agents | 1 | 2020 | 40 | 0.180 |
Why?
|
Azathioprine | 1 | 2020 | 354 | 0.160 |
Why?
|
Vasculitis | 1 | 2023 | 522 | 0.160 |
Why?
|
Mycophenolic Acid | 1 | 2020 | 349 | 0.160 |
Why?
|
Risk Assessment | 2 | 2021 | 23972 | 0.150 |
Why?
|
Remission Induction | 1 | 2024 | 2391 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20556 | 0.150 |
Why?
|
Asymptomatic Diseases | 1 | 2020 | 587 | 0.140 |
Why?
|
Prednisone | 1 | 2021 | 1562 | 0.130 |
Why?
|
Optic Atrophy | 1 | 2014 | 79 | 0.120 |
Why?
|
Methotrexate | 1 | 2020 | 1716 | 0.110 |
Why?
|
Muscle Spasticity | 1 | 2014 | 156 | 0.110 |
Why?
|
Spinocerebellar Ataxias | 1 | 2014 | 105 | 0.110 |
Why?
|
Trisomy | 1 | 2014 | 260 | 0.110 |
Why?
|
Retrospective Studies | 6 | 2023 | 80566 | 0.110 |
Why?
|
Humans | 19 | 2024 | 760617 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2018 | 1469 | 0.100 |
Why?
|
Sinusitis | 1 | 2021 | 991 | 0.100 |
Why?
|
Incidence | 2 | 2020 | 21337 | 0.090 |
Why?
|
Vaccination | 1 | 2023 | 3370 | 0.090 |
Why?
|
Dietary Supplements | 1 | 2024 | 3411 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6305 | 0.090 |
Why?
|
Prognosis | 3 | 2024 | 29600 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4571 | 0.090 |
Why?
|
Genetic Linkage | 1 | 2014 | 2340 | 0.080 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39063 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2020 | 2152 | 0.080 |
Why?
|
Aged | 5 | 2024 | 169042 | 0.070 |
Why?
|
Multiple System Atrophy | 1 | 2009 | 130 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4745 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10754 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2021 | 4236 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12447 | 0.070 |
Why?
|
Treatment Outcome | 2 | 2024 | 64568 | 0.060 |
Why?
|
Female | 8 | 2024 | 392148 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5293 | 0.060 |
Why?
|
Adult | 5 | 2021 | 220969 | 0.060 |
Why?
|
Nipecotic Acids | 1 | 2023 | 36 | 0.050 |
Why?
|
Risk Factors | 3 | 2020 | 74115 | 0.050 |
Why?
|
alpha-Synuclein | 1 | 2009 | 752 | 0.050 |
Why?
|
Male | 7 | 2024 | 360358 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2014 | 17878 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13495 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11459 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7402 | 0.040 |
Why?
|
Peroxidase | 1 | 2023 | 610 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54360 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10704 | 0.040 |
Why?
|
Middle Aged | 4 | 2021 | 220584 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2023 | 1068 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 39913 | 0.030 |
Why?
|
Nephrotic Syndrome | 1 | 2020 | 390 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 3800 | 0.030 |
Why?
|
Parkinson Disease | 1 | 2009 | 2878 | 0.030 |
Why?
|
United States | 2 | 2021 | 72272 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6561 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2014 | 15908 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2014 | 410 | 0.030 |
Why?
|
France | 1 | 2014 | 492 | 0.030 |
Why?
|
Gene Frequency | 2 | 2009 | 3601 | 0.030 |
Why?
|
Genotype | 2 | 2014 | 12978 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4539 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2014 | 4611 | 0.020 |
Why?
|
Japan | 1 | 2009 | 1372 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41457 | 0.010 |
Why?
|
Medicare | 1 | 2021 | 6765 | 0.010 |
Why?
|
Genome-Wide Association Study | 2 | 2009 | 12661 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9604 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16571 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9643 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 59179 | 0.010 |
Why?
|
Concepts
(100)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_